Journal article
Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.
- Abstract:
-
Fidaxomicin has recently been approved for the treatment of Clostridium difficile infection (CDI). As part of phase III studies, plasma and fecal samples were analyzed for concentrations of fidaxomicin and its metabolite, OP-1118. Plasma samples were collected before and after dose receipt on the first and last days of therapy, and fecal samples were collected on the last day of therapy. Samples were analyzed for fidaxomicin and OP-1118 (metabolite), using validated liquid chromatography/tand...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
- Volume:
- 55 Suppl 2
- Issue:
- SUPPL.2
- Pages:
- S116-S120
- Publication date:
- 2012-08-01
- DOI:
- EISSN:
-
1537-6591
- ISSN:
-
1058-4838
- Source identifiers:
-
344572
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:344572
- UUID:
-
uuid:8de5c1d6-5adf-4692-a968-0b2ceeb1bdf8
- Local pid:
- pubs:344572
- Deposit date:
- 2013-11-16
Terms of use
- Copyright date:
- 2012
If you are the owner of this record, you can report an update to it here: Report update to this record